NURS572 Advanced Pharmacotherapeutics Exam 3 Prep
Document | 2026/2027 Edition | 250 Verified Questions
NURS572 Advanced Pharmacotherapeutics Exam 3 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for NURS572 Advanced Pharmacotherapeutics, Exam
3, features 250 verified practice questions with correct answers and detailed rationales. Designed for
University of Arizona nursing students, it covers key pharmacotherapeutic concepts including drug
mechanisms, adverse effects, and clinical decision-making. Each question reflects the latest 2026/2027
course guidelines to ensure relevance and accuracy. This test bank is an essential tool for mastering
advanced pharmacotherapeutics and achieving a high score on the exam.
Key Features:
Pharmacokinetics and pharmacodynamics of major drug classes
Drug interactions, contraindications, and adverse effects
Clinical application in managing complex patient cases
Evidence-based prescribing and monitoring strategies
Special populations considerations (pediatric, geriatric, pregnancy)
Updates for 2026:
- Updated to reflect 2026/2027 course curriculum changes
- Incorporated new FDA-approved medications and black box warnings
- Revised rationales to align with latest clinical practice guidelines
- Added questions on emerging pharmacotherapies for chronic diseases
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This exam preparation document for NURS572 Advanced Pharmacotherapeutics, Exam 3, contains 250
meticulously verified questions with correct answers and comprehensive rationales. The content is organized to
reflect the University of Arizona's 2026/2027 curriculum, focusing on advanced pharmacotherapeutic principles
essential for nurse practitioners. Topics include pharmacokinetics, pharmacodynamics, drug interactions, adverse
effects, and clinical decision-making across major drug classes such as cardiovascular, endocrine, neurological,
and psychiatric medications. Each question is designed to test higher-order thinking and application in complex
patient scenarios. Rationales provide evidence-based explanations, including mechanisms of action, therapeutic
uses, and monitoring parameters. This resource is ideal for students seeking to reinforce their knowledge and excel
in the exam, with content updated to incorporate the latest FDA approvals and clinical guidelines. The test bank
emphasizes safe prescribing practices and management of special populations, ensuring comprehensive
preparation for advanced practice nursing roles.
Keywords:
Advanced Pharmacotherapeutics, NURS572, Exam 3, Practice Test Bank, 250 Questions, University of Arizona,
Pharmacokinetics, Clinical Decision-Making
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct, along with
explanations for why the other options are incorrect. Rationales include relevant drug mechanisms, clinical
guidelines, and key nursing considerations to reinforce learning.
Compliance Checklist:
All questions are verified and aligned with 2026/2027 NURS572 curriculum
Page 1
, Rationales cite current clinical practice guidelines and FDA labeling
Content covers all major drug classes tested on Exam 3
Questions are formatted to match exam style and difficulty
Special population considerations are integrated throughout
Content Area Overview:
Content Area Questions Key Topics Weight
Cardiovascular 1-50 Antihypertensives, antiarrhythmics, heart 20%
Pharmacotherapeutics failure medications, anticoagulants
Endocrine Pharmacotherapeutics 51-100 Diabetes medications, thyroid agents, 20%
corticosteroids, sex hormones
Neurological and Psychiatric 101-150 Antidepressants, antipsychotics, 20%
Pharmacotherapeutics antiepileptics, analgesics
Infectious Disease 151-200 Antibiotics, antivirals, antifungals, 20%
Pharmacotherapeutics immunizations
Special Populations and Safety 201-250 Pediatric dosing, geriatric considerations, 20%
pregnancy categories, drug interactions
Page 2
,Q1. A patient with treatment-resistant hypertension is being evaluated for a new antihypertensive regimen.
The patient has a history of asthma and is currently taking a beta-blocker, an ACE inhibitor, and a thiazide
diuretic. Given the resistance, which of the following mechanisms best explains why adding a calcium
channel blocker (CCB) may be more effective than switching to a different beta-blocker?
A. CCBs directly inhibit renin release, providing additional blockade of the RAAS pathway.
B. CCBs cause direct vasodilation and reduce peripheral vascular resistance, which is often elevated in resistant
hypertension, while beta-blockers may increase vascular resistance via unopposed alpha-receptor activity.
C. CCBs increase cardiac output, counteracting the negative inotropic effects of beta-blockers.
D. CCBs enhance the natriuretic effect of thiazide diuretics by increasing renal blood flow.
Correct Answer: B. CCBs cause direct vasodilation and reduce peripheral vascular resistance, which is often
elevated in resistant hypertension, while beta-blockers may increase vascular resistance via unopposed
alpha-receptor activity.
Rationale: In resistant hypertension, elevated peripheral vascular resistance is a key contributor. CCBs (e.g.,
amlodipine) cause direct arteriolar vasodilation, reducing afterload. Beta-blockers, particularly
non-cardioselective ones, can leave alpha-receptors unopposed, potentially increasing vascular resistance.
Additionally, the patient's asthma contraindicates non-cardioselective beta-blockers. Option A is incorrect because
CCBs do not directly inhibit renin; they may increase renin due to vasodilation. Option C is incorrect because
CCBs do not increase cardiac output in hypertensive patients; they have negative chronotropic effects. Option D is
incorrect because CCBs do not significantly affect renal blood flow or natriuresis.
Why Wrong:
A - CCBs do not directly inhibit renin; they may actually increase renin release via reflex sympathetic
activation.
C - CCBs generally decrease cardiac output due to negative chronotropic and inotropic effects, not increase it.
D - CCBs do not have significant natriuretic effects; thiazide diuretics act on the distal tubule independently.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38, 39.
Q2. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73 m²) is currently on
metformin, which is now contraindicated. The patient's HbA1c is 8.5%. Which of the following
pharmacotherapeutic strategies is most appropriate, considering both efficacy and safety in advanced CKD?
A. Initiate a sulfonylurea (e.g., glipizide) and titrate to achieve glycemic targets, monitoring for hypoglycemia.
B. Start a DPP-4 inhibitor (e.g., sitagliptin) with dose adjustment for renal function, and consider adding an
SGLT2 inhibitor.
C. Begin insulin therapy with a basal-bolus regimen, as most oral agents are contraindicated or ineffective in
stage 4 CKD.
D. Use a GLP-1 receptor agonist (e.g., liraglutide) without dose adjustment, as it is safe in all stages of CKD.
Correct Answer: C. Begin insulin therapy with a basal-bolus regimen, as most oral agents are
contraindicated or ineffective in stage 4 CKD.
Rationale: In advanced CKD (eGFR < 30), metformin is contraindicated due to lactic acidosis risk. Sulfonylureas
(except glipizide) accumulate and increase hypoglycemia risk; glipizide is safer but still carries risk. DPP-4
inhibitors require dose adjustment but are not first-line for this HbA1c. GLP-1 agonists are not recommended with
eGFR < 30. Insulin therapy is the most appropriate and safest option, as it allows precise titration and is not
limited by renal function. Option A is less safe due to hypoglycemia. Option B is suboptimal because SGLT2
inhibitors are contraindicated when eGFR < 30. Option D is incorrect because most GLP-1 agonists require dose
adjustment or are contraindicated in severe CKD.
Why Wrong:
A - Sulfonylureas, even glipizide, increase hypoglycemia risk in CKD and are not preferred for an HbA1c of
8.5%.
B - SGLT2 inhibitors are contraindicated when eGFR < 30 mL/min; DPP-4 inhibitors require dose adjustment
but are less potent.
Page 3
, D - GLP-1 receptor agonists, except perhaps dulaglutide, are not recommended in severe CKD due to limited
safety data and gastrointestinal effects.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 68; ADA Standards of Medical Care in
Diabetes, 2025.
Q3. A patient with a history of recurrent Clostridioides difficile infection (CDI) is being treated with oral
vancomycin. After completing the course, the patient develops another recurrence. Which of the following
mechanisms is most likely contributing to the failure of vancomycin in this setting?
A. Vancomycin induces the formation of vancomycin-resistant enterococci (VRE), which cross-protect C.
difficile.
B. Vancomycin has poor activity against C. difficile spores, allowing germination after therapy cessation.
C. Vancomycin is inactivated by the acidic pH of the colon, reducing its efficacy.
D. Vancomycin is extensively absorbed systemically, leading to subtherapeutic fecal concentrations.
Correct Answer: B. Vancomycin has poor activity against C. difficile spores, allowing germination after
therapy cessation.
Rationale: Oral vancomycin is effective against vegetative C. difficile but does not eradicate spores. After
treatment, spores can germinate, leading to recurrence, especially in patients with disrupted gut microbiota. Option
A is incorrect because vancomycin does not induce VRE cross-protection; VRE are resistant to vancomycin but this
does not directly cause CDI recurrence. Option C is incorrect because vancomycin is stable in colonic pH. Option
D is incorrect because oral vancomycin is minimally absorbed, achieving high fecal concentrations.
Why Wrong:
A - Vancomycin use can select for VRE, but VRE do not protect C. difficile spores; recurrence is due to spore
persistence.
C - Vancomycin is stable across a wide pH range and remains active in the colon.
D - Oral vancomycin is poorly absorbed, resulting in high intraluminal concentrations, not subtherapeutic.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 83; IDSA Guidelines for C. difficile
Infection, 2024.
Q4. A patient with a recent diagnosis of atrial fibrillation is started on warfarin. The patient also takes
omeprazole for GERD. After one week, the INR is 1.2. Which of the following best explains the lack of
therapeutic anticoagulation?
A. Omeprazole induces CYP2C9, increasing warfarin metabolism and reducing its effect.
B. Omeprazole inhibits the absorption of vitamin K, paradoxically increasing warfarin sensitivity.
C. Omeprazole reduces the bioavailability of warfarin by binding to it in the stomach.
D. Warfarin has a delayed onset of action due to its mechanism of depleting clotting factors with varying
half-lives.
Correct Answer: D. Warfarin has a delayed onset of action due to its mechanism of depleting clotting factors
with varying half-lives.
Rationale: Warfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase, leading to depletion
of functional clotting factors II, VII, IX, and X. Factor VII has the shortest half-life (6 hours), so initial INR rise
reflects factor VII depletion, but full therapeutic effect requires depletion of factor II (half-life ~60 hours). Thus,
even with loading doses, therapeutic INR is typically not achieved until 3-5 days. Option A is incorrect because
omeprazole is a weak inhibitor of CYP2C19, not a significant inducer of CYP2C9. Option B is incorrect;
omeprazole does not significantly affect vitamin K absorption. Option C is incorrect; no direct binding occurs.
Why Wrong:
A - Omeprazole does not induce CYP2C9; it is a substrate of CYP2C19 and may inhibit it, but not relevant to
warfarin metabolism.
B - Omeprazole does not inhibit vitamin K absorption; warfarin sensitivity is not increased by omeprazole.
C - There is no evidence of direct binding between omeprazole and warfarin reducing bioavailability.
Page 4
Document | 2026/2027 Edition | 250 Verified Questions
NURS572 Advanced Pharmacotherapeutics Exam 3 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for NURS572 Advanced Pharmacotherapeutics, Exam
3, features 250 verified practice questions with correct answers and detailed rationales. Designed for
University of Arizona nursing students, it covers key pharmacotherapeutic concepts including drug
mechanisms, adverse effects, and clinical decision-making. Each question reflects the latest 2026/2027
course guidelines to ensure relevance and accuracy. This test bank is an essential tool for mastering
advanced pharmacotherapeutics and achieving a high score on the exam.
Key Features:
Pharmacokinetics and pharmacodynamics of major drug classes
Drug interactions, contraindications, and adverse effects
Clinical application in managing complex patient cases
Evidence-based prescribing and monitoring strategies
Special populations considerations (pediatric, geriatric, pregnancy)
Updates for 2026:
- Updated to reflect 2026/2027 course curriculum changes
- Incorporated new FDA-approved medications and black box warnings
- Revised rationales to align with latest clinical practice guidelines
- Added questions on emerging pharmacotherapies for chronic diseases
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This exam preparation document for NURS572 Advanced Pharmacotherapeutics, Exam 3, contains 250
meticulously verified questions with correct answers and comprehensive rationales. The content is organized to
reflect the University of Arizona's 2026/2027 curriculum, focusing on advanced pharmacotherapeutic principles
essential for nurse practitioners. Topics include pharmacokinetics, pharmacodynamics, drug interactions, adverse
effects, and clinical decision-making across major drug classes such as cardiovascular, endocrine, neurological,
and psychiatric medications. Each question is designed to test higher-order thinking and application in complex
patient scenarios. Rationales provide evidence-based explanations, including mechanisms of action, therapeutic
uses, and monitoring parameters. This resource is ideal for students seeking to reinforce their knowledge and excel
in the exam, with content updated to incorporate the latest FDA approvals and clinical guidelines. The test bank
emphasizes safe prescribing practices and management of special populations, ensuring comprehensive
preparation for advanced practice nursing roles.
Keywords:
Advanced Pharmacotherapeutics, NURS572, Exam 3, Practice Test Bank, 250 Questions, University of Arizona,
Pharmacokinetics, Clinical Decision-Making
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct, along with
explanations for why the other options are incorrect. Rationales include relevant drug mechanisms, clinical
guidelines, and key nursing considerations to reinforce learning.
Compliance Checklist:
All questions are verified and aligned with 2026/2027 NURS572 curriculum
Page 1
, Rationales cite current clinical practice guidelines and FDA labeling
Content covers all major drug classes tested on Exam 3
Questions are formatted to match exam style and difficulty
Special population considerations are integrated throughout
Content Area Overview:
Content Area Questions Key Topics Weight
Cardiovascular 1-50 Antihypertensives, antiarrhythmics, heart 20%
Pharmacotherapeutics failure medications, anticoagulants
Endocrine Pharmacotherapeutics 51-100 Diabetes medications, thyroid agents, 20%
corticosteroids, sex hormones
Neurological and Psychiatric 101-150 Antidepressants, antipsychotics, 20%
Pharmacotherapeutics antiepileptics, analgesics
Infectious Disease 151-200 Antibiotics, antivirals, antifungals, 20%
Pharmacotherapeutics immunizations
Special Populations and Safety 201-250 Pediatric dosing, geriatric considerations, 20%
pregnancy categories, drug interactions
Page 2
,Q1. A patient with treatment-resistant hypertension is being evaluated for a new antihypertensive regimen.
The patient has a history of asthma and is currently taking a beta-blocker, an ACE inhibitor, and a thiazide
diuretic. Given the resistance, which of the following mechanisms best explains why adding a calcium
channel blocker (CCB) may be more effective than switching to a different beta-blocker?
A. CCBs directly inhibit renin release, providing additional blockade of the RAAS pathway.
B. CCBs cause direct vasodilation and reduce peripheral vascular resistance, which is often elevated in resistant
hypertension, while beta-blockers may increase vascular resistance via unopposed alpha-receptor activity.
C. CCBs increase cardiac output, counteracting the negative inotropic effects of beta-blockers.
D. CCBs enhance the natriuretic effect of thiazide diuretics by increasing renal blood flow.
Correct Answer: B. CCBs cause direct vasodilation and reduce peripheral vascular resistance, which is often
elevated in resistant hypertension, while beta-blockers may increase vascular resistance via unopposed
alpha-receptor activity.
Rationale: In resistant hypertension, elevated peripheral vascular resistance is a key contributor. CCBs (e.g.,
amlodipine) cause direct arteriolar vasodilation, reducing afterload. Beta-blockers, particularly
non-cardioselective ones, can leave alpha-receptors unopposed, potentially increasing vascular resistance.
Additionally, the patient's asthma contraindicates non-cardioselective beta-blockers. Option A is incorrect because
CCBs do not directly inhibit renin; they may increase renin due to vasodilation. Option C is incorrect because
CCBs do not increase cardiac output in hypertensive patients; they have negative chronotropic effects. Option D is
incorrect because CCBs do not significantly affect renal blood flow or natriuresis.
Why Wrong:
A - CCBs do not directly inhibit renin; they may actually increase renin release via reflex sympathetic
activation.
C - CCBs generally decrease cardiac output due to negative chronotropic and inotropic effects, not increase it.
D - CCBs do not have significant natriuretic effects; thiazide diuretics act on the distal tubule independently.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38, 39.
Q2. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73 m²) is currently on
metformin, which is now contraindicated. The patient's HbA1c is 8.5%. Which of the following
pharmacotherapeutic strategies is most appropriate, considering both efficacy and safety in advanced CKD?
A. Initiate a sulfonylurea (e.g., glipizide) and titrate to achieve glycemic targets, monitoring for hypoglycemia.
B. Start a DPP-4 inhibitor (e.g., sitagliptin) with dose adjustment for renal function, and consider adding an
SGLT2 inhibitor.
C. Begin insulin therapy with a basal-bolus regimen, as most oral agents are contraindicated or ineffective in
stage 4 CKD.
D. Use a GLP-1 receptor agonist (e.g., liraglutide) without dose adjustment, as it is safe in all stages of CKD.
Correct Answer: C. Begin insulin therapy with a basal-bolus regimen, as most oral agents are
contraindicated or ineffective in stage 4 CKD.
Rationale: In advanced CKD (eGFR < 30), metformin is contraindicated due to lactic acidosis risk. Sulfonylureas
(except glipizide) accumulate and increase hypoglycemia risk; glipizide is safer but still carries risk. DPP-4
inhibitors require dose adjustment but are not first-line for this HbA1c. GLP-1 agonists are not recommended with
eGFR < 30. Insulin therapy is the most appropriate and safest option, as it allows precise titration and is not
limited by renal function. Option A is less safe due to hypoglycemia. Option B is suboptimal because SGLT2
inhibitors are contraindicated when eGFR < 30. Option D is incorrect because most GLP-1 agonists require dose
adjustment or are contraindicated in severe CKD.
Why Wrong:
A - Sulfonylureas, even glipizide, increase hypoglycemia risk in CKD and are not preferred for an HbA1c of
8.5%.
B - SGLT2 inhibitors are contraindicated when eGFR < 30 mL/min; DPP-4 inhibitors require dose adjustment
but are less potent.
Page 3
, D - GLP-1 receptor agonists, except perhaps dulaglutide, are not recommended in severe CKD due to limited
safety data and gastrointestinal effects.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 68; ADA Standards of Medical Care in
Diabetes, 2025.
Q3. A patient with a history of recurrent Clostridioides difficile infection (CDI) is being treated with oral
vancomycin. After completing the course, the patient develops another recurrence. Which of the following
mechanisms is most likely contributing to the failure of vancomycin in this setting?
A. Vancomycin induces the formation of vancomycin-resistant enterococci (VRE), which cross-protect C.
difficile.
B. Vancomycin has poor activity against C. difficile spores, allowing germination after therapy cessation.
C. Vancomycin is inactivated by the acidic pH of the colon, reducing its efficacy.
D. Vancomycin is extensively absorbed systemically, leading to subtherapeutic fecal concentrations.
Correct Answer: B. Vancomycin has poor activity against C. difficile spores, allowing germination after
therapy cessation.
Rationale: Oral vancomycin is effective against vegetative C. difficile but does not eradicate spores. After
treatment, spores can germinate, leading to recurrence, especially in patients with disrupted gut microbiota. Option
A is incorrect because vancomycin does not induce VRE cross-protection; VRE are resistant to vancomycin but this
does not directly cause CDI recurrence. Option C is incorrect because vancomycin is stable in colonic pH. Option
D is incorrect because oral vancomycin is minimally absorbed, achieving high fecal concentrations.
Why Wrong:
A - Vancomycin use can select for VRE, but VRE do not protect C. difficile spores; recurrence is due to spore
persistence.
C - Vancomycin is stable across a wide pH range and remains active in the colon.
D - Oral vancomycin is poorly absorbed, resulting in high intraluminal concentrations, not subtherapeutic.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 83; IDSA Guidelines for C. difficile
Infection, 2024.
Q4. A patient with a recent diagnosis of atrial fibrillation is started on warfarin. The patient also takes
omeprazole for GERD. After one week, the INR is 1.2. Which of the following best explains the lack of
therapeutic anticoagulation?
A. Omeprazole induces CYP2C9, increasing warfarin metabolism and reducing its effect.
B. Omeprazole inhibits the absorption of vitamin K, paradoxically increasing warfarin sensitivity.
C. Omeprazole reduces the bioavailability of warfarin by binding to it in the stomach.
D. Warfarin has a delayed onset of action due to its mechanism of depleting clotting factors with varying
half-lives.
Correct Answer: D. Warfarin has a delayed onset of action due to its mechanism of depleting clotting factors
with varying half-lives.
Rationale: Warfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase, leading to depletion
of functional clotting factors II, VII, IX, and X. Factor VII has the shortest half-life (6 hours), so initial INR rise
reflects factor VII depletion, but full therapeutic effect requires depletion of factor II (half-life ~60 hours). Thus,
even with loading doses, therapeutic INR is typically not achieved until 3-5 days. Option A is incorrect because
omeprazole is a weak inhibitor of CYP2C19, not a significant inducer of CYP2C9. Option B is incorrect;
omeprazole does not significantly affect vitamin K absorption. Option C is incorrect; no direct binding occurs.
Why Wrong:
A - Omeprazole does not induce CYP2C9; it is a substrate of CYP2C19 and may inhibit it, but not relevant to
warfarin metabolism.
B - Omeprazole does not inhibit vitamin K absorption; warfarin sensitivity is not increased by omeprazole.
C - There is no evidence of direct binding between omeprazole and warfarin reducing bioavailability.
Page 4
